IL280421B2 - Cancer treatment by antibody - Google Patents

Cancer treatment by antibody

Info

Publication number
IL280421B2
IL280421B2 IL280421A IL28042121A IL280421B2 IL 280421 B2 IL280421 B2 IL 280421B2 IL 280421 A IL280421 A IL 280421A IL 28042121 A IL28042121 A IL 28042121A IL 280421 B2 IL280421 B2 IL 280421B2
Authority
IL
Israel
Prior art keywords
specific binding
binding molecule
cancer
seq
antibody
Prior art date
Application number
IL280421A
Other languages
English (en)
Hebrew (he)
Other versions
IL280421A (en
IL280421B1 (en
Inventor
Barry Wood Christopher
C Flatau Tina
Dempsey Fiona
Crichton Scott
Original Assignee
Medannex Ltd
Barry Wood Christopher
C Flatau Tina
Dempsey Fiona
Crichton Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medannex Ltd, Barry Wood Christopher, C Flatau Tina, Dempsey Fiona, Crichton Scott filed Critical Medannex Ltd
Publication of IL280421A publication Critical patent/IL280421A/en
Publication of IL280421B1 publication Critical patent/IL280421B1/en
Publication of IL280421B2 publication Critical patent/IL280421B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL280421A 2018-08-10 2019-08-12 Cancer treatment by antibody IL280421B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1813137.5A GB201813137D0 (en) 2018-08-10 2018-08-10 Cancer treatment with an antibody
PCT/EP2019/071627 WO2020030827A1 (en) 2018-08-10 2019-08-12 Cancer treatment with an antibody

Publications (3)

Publication Number Publication Date
IL280421A IL280421A (en) 2021-03-25
IL280421B1 IL280421B1 (en) 2024-02-01
IL280421B2 true IL280421B2 (en) 2024-06-01

Family

ID=63667034

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280421A IL280421B2 (en) 2018-08-10 2019-08-12 Cancer treatment by antibody

Country Status (12)

Country Link
US (1) US11858982B2 (enExample)
EP (1) EP3833404A1 (enExample)
JP (2) JP7428696B2 (enExample)
KR (1) KR20210088523A (enExample)
CN (1) CN112770786B (enExample)
AU (1) AU2019319092B2 (enExample)
BR (1) BR112021002435A2 (enExample)
GB (1) GB201813137D0 (enExample)
IL (1) IL280421B2 (enExample)
MX (1) MX2021001604A (enExample)
TW (1) TW202014437A (enExample)
WO (1) WO2020030827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250025553A1 (en) 2021-11-18 2025-01-23 Medannex Ltd. Combination therapy for cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219299A1 (en) 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
US20040219572A1 (en) 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
EP1670510A1 (en) 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
CN100571785C (zh) * 2006-09-06 2009-12-23 中国医学科学院北京协和医院 Annexin A3与癌症的铂类化疗药物耐药性的相关性
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
EP2580241B1 (en) * 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Annexin 1 antibody
CN102898527B (zh) 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
KR20150029457A (ko) 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
US20160291025A1 (en) 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
US20210292400A1 (en) 2018-05-17 2021-09-23 Yiping W. Han Methods for treating, preventing and detecting the prognosis of colorectal cancer
US20210353721A1 (en) 2018-08-07 2021-11-18 The Brigham And Women's Hospital, Inc. Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1
US20200171165A1 (en) 2018-11-30 2020-06-04 Proteogenomics Research Institute for Systems Medicine Enhanced targeted delivery of therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XINYUAN PAN ET AL,, DOWNREGULATION OF ANNEXIN A1 BY SHORT HAIRPIN RNA INHIBITS THE OSTEOGENIC DIFFERENTIATION OF RAT BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, 1 August 2015 (2015-08-01) *

Also Published As

Publication number Publication date
BR112021002435A2 (pt) 2021-05-04
US11858982B2 (en) 2024-01-02
CA3107674A1 (en) 2020-02-13
KR20210088523A (ko) 2021-07-14
EP3833404A1 (en) 2021-06-16
CN112770786B (zh) 2023-10-27
CN112770786A (zh) 2021-05-07
JP2024041851A (ja) 2024-03-27
TW202014437A (zh) 2020-04-16
WO2020030827A1 (en) 2020-02-13
MX2021001604A (es) 2021-04-19
US20210238269A1 (en) 2021-08-05
IL280421A (en) 2021-03-25
JP7428696B2 (ja) 2024-02-06
JP2021534121A (ja) 2021-12-09
GB201813137D0 (en) 2018-09-26
AU2019319092A1 (en) 2021-03-18
AU2019319092B2 (en) 2026-04-02
JP7728035B2 (ja) 2025-08-22
IL280421B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US20220185897A1 (en) Anti-axl antibodies
JP7458686B2 (ja) 抗ネクチン－４抗体、それを含むコンジュゲート、及びその適用
CA2952113A1 (en) Anti-axl antibodies
CN112292397A (zh) 抗ox40抗体及其用途
WO2023143315A1 (zh) 一种靶向ror1的抗体或其抗原结合片段及其应用
JP7728035B2 (ja) 抗体による癌治療
TW202409076A (zh) 抗slc34a2單株抗體及其用途
CA3107674C (en) Cancer treatment with an antibody
US20250025553A1 (en) Combination therapy for cancer
CN118524851A (zh) 用于癌症的组合疗法
HK40097833A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
HK40039579A (en) Anti-ox40 antibodies and uses thereof
HK40039579B (en) Anti-ox40 antibodies and uses thereof